Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02153723 · ClinicalTrials.gov registry record · Phase 2
Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
A Phase 2 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02153723 is a Phase 2 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT02153723, a Phase 2 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
A phase 2 open label trial to test a potential drug treatment for Rett syndrome, the leading known genetic cause of severe neurological impairment in girls. The drug, Copaxone (generic name - Glatiramer acetate) is medication FDA approved for the treatment of multiple sclerosis. Copaxone's high safety profile has been documented in large cohorts of patients for more than 12 years.
Interventions
- DRUG Glatiramer Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02153723
The ClinicalTrials.gov registry entry for NCT02153723 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glatiramer Acetate is the first listed.
NCT02153723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02153723 about?
NCT02153723 is a clinical study titled "Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)". A phase 2 open label trial to test a potential drug treatment for Rett syndrome, the leading known genetic cause of severe neurological impairment in girls. The drug, Copaxone (generic name - Glatiramer acetate) is medication FDA approved for the treatment of multiple sclerosis. Copaxone's high safe...
What is the current status of trial NCT02153723?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2013-08. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02153723?
The interventions under investigation include: Glatiramer Acetate (DRUG).
Who is sponsoring clinical trial NCT02153723?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.